SlideShare uma empresa Scribd logo
1 de 50
The Pistoia
                                  Alliance
                                                pistoiaalliance.org




A Construct for Pre-competitive Collaborations
   Chris L. Waller, Ph.D.
   Pfizer



Collaborative Drug Discovery Annual Meeting
San Francisco, CA
October 2009
Agenda

• Introduction
• Origins of Pistoia
  – History
  – Industry Drivers
  – Technology Trends
• Scope and Operations of Pistoia
  – Mission, Membership, Governance
  – Projects and Deliverables
• Discussion
R&D: Long, Expensive, and Risky
 Target                          Chemical                                 Clinical
                                                                                                            Launch
 Selection                       Selection                                 Trials
                                                                 Discovery
                                                                 (2-10 years)

                                                                     Pre-clinical Testing
                                                                     Laboratory and animal testing
                                                             Phase 1
                                                             20-80 healthy volunteers - safety and dosage
                                                                            Phase 2
                                                                            100-300 patient volunteers efficacy & safety

                                             Phase 3
        3,000-5,000 patient volunteers used to monitor
                    adverse reactions to long-term use
                                                                                                      FDA Review/
                                                                                                      Approval
Years

0           2             4             6                8         10            12            14            16



                                 Cost = $1.3B/new drug
Productivity is Decreasing
   Industry R&D                                                                                   Annual NME
      Expense                                                                                      Approvals
     ($ Billions)
       $35                                                                                               200
                               R&D Investment                                                            180
       $30
                               NME Approvals                                                             160
       $25                                                                                               140

       $20
                                                                                                         120
                                                                                                         100
       $15
                                                                                                         80
       $10                                                                                               60
                                                                                                         40
         $5
                                                                                                         20
         $0                                                                                              0
              1980              1984             1988              1992             1996   2000   2004

Source: PhRMA, FDA, Lehman Brothers; The 2004 Industry R&D Expense is an estimate
Chris’s Mission Statement
  • Foster collaborations between
    pharmaceutical, biotechnology,
    technology, academic, and
    government organizations in pre-
    competitive space to develop and
    promote the use of standards,
    identify partnerships, and transfer
    technology in order to drive greater
    process efficiency and lower costs.
Pre-competitive
  • Refers to standards, data, or
    processes that are common across
    an industry and where the adoption,
    use, or prosecution of which
    provides no competitive advantage
    relative to peers.
Leading Healthcare Data Exchange
Standards
             Clinical                            Materials
                                                Management                          Billing,
             System
                                                                                    claims
                           HL7                  X12N                            reimbursement
    Retail Pharmacy                                                   X12N / HL7 (Non-US only)
Orders & Reimbursement

                                 NCPDP                                 HL7          Immunization
                                             Healthcare                               Database
     Waveforms           HL7                Information
                                               System
                                                                             HL7, X12N

       Images,                  DICOM                                           Agency Reporting
       pictures

                                                             HL7                   HL7, X12N
                                    IEEE MIB,
                                      ASTM
                    Bedside                                 Adverse                        Provider
                  Instruments                           Events Reporting                  Repository

                                                                                     Image from Abdul-Malik Shakir
Background—How it all started

• In Pistoia, Italy

• Meeting of GSK, AZ, Pfizer
  and Novartis—identified
  similar challenges and
  frustrations in the
  IT/Informatics sector of
  Pharmaceutical Discovery
                                8
Industry Driver: Externalization
Cost pressures, disruptive technologies, and other forces
often drive business processes to be externalized.

    Fully Internal   PHARMA              DESIGN     SYNTHESIZE      REGISTER      DISTRIBUTE   ASSAY    REPORT


        Model


     Selectively
                              PHARMA




                                         DESIGN                           DISTRIBUTE
                                                                                                        PHARMA
     Integrated
                              CHEM CRO




       Model                                      SYNTHESIZE
                                                                                                        CHEM
                              BIO CRO




                                                                                       ASSAY
                                                                                                         BIO
                              DATA CRO




                                                               REGISTER                        REPORT
                                                                                                        DATA
Emerging Net-centric Pharma
Processes

   PHARMA              CRO
      1                 1

   PHARMA              CRO
      2                 2

   PHARMA              CRO
      3                 3

                       CRO
                        4
Inconsistent Semantics degrade
Effective Communication
                 C

                 B

                 A


         The result from our
       proprietary assay is “B”

CRO
         But we only record numbers
               in our assays!!
                                      PHARMA
Greater Challenge: Unknown Semantic
Collisions




Revealing assumptions is an essential
component of effective communication.   Image/quote from Abdul-Malik Shakir
Opportunity: Changing Tech
Landscape
More Robust Technologies
• Web 2.0
• Services-Oriented Architecture
• Software-as-a-Service
• Open Source Initiatives

More Robust External Content
• Publicly available chem and bio sources
• Richer literature content
• Academic Sources of Tools and Data
The Path Forward:
 Standardize, Simplify, Centralize

• Standardize our interfaces and messages
• Simplify our cross-industry architectures
  and support models
• Centralize services to reap economies of
  scale and scope
Mission of Pistoia
• Pistoia is the BRIDGE to cross the chasm
  to a more agile pre-competitive
  environment




     STANDARDIZE   SIMPLIFY   CENTRALIZE
       PISTOIA     MEMBERS     SUPPLIERS
Learn from Other Industries

Transportation

                         Geospatial
Banking

Retail                    Clinical


Automotive
                        Healthcare
Pistoia Description and Purpose

Mission
To streamline pre-competitive workflow
elements of pharmaceutical research and
development by specifying common business
terms, relationships and processes
Goal
• Develop taxonomies and vocabularies, application
  interface specifications, data dictionaries, data
  models, etc.
• Establish standards that will be embraced by
  producers and consumers of pre-competitive
  workflows                                           17
Pistoia Membership
  as of: August 26, 2009


>65 Individuals from 18 member organizations
Pistoia Alliance Organisation

                             Develops roadmap
   Board of         Final approval of technical standards
   Directors         Voting Members (pharma, biotech)
                  Non-Voting Members (vendors, academics)




    Officers    President, Secretary, Treasurer, PM, Communica
                                      tions


                              Develop standards
    Technical       Submit standards to Gov & Strat Board
   Committee            Finalize standard and publish
                Observe use of standard and evolve if necessary
                                                                  19
Pistoia Standards Process

Governance &     Working Groups               Pistoia
Operations                                    Community

Governance                                    Software and
& Strategy       submit
                                              Service
Board                                         Providers
                                   propose,
                  Technical &      comment
                  Standards                   Pharma/
Operational       Teams                       BioTech/Agro
Team                              publish

                                              Not for
          coordinate                          Profit
                                              (e.g. IMI, EBI)
                                                                20
Pistoia Domains
Pistoia Domains
Focused on business workflows/supply chains


       Enabling
                        Knowledge and Information
      Vocabulary
                                Services
      Visualisation


       Workflow
                           Application Integration
         Others


                      Biology     Chemistry   Translational
                        Data        Data          Data
                      Services     Services     Services
Capturing Demand using Domain Framework
 Need a
 disease                                         How to enrich
ontology         Need a          How to enrich literature with
                 disease         literature with semantic tags
                ontology          semantic tags

         What is this raw                             How to show
                                   How to show
 What is this How did you
       data? raw                                  chemical structures
                               chemical structures
data? Howcalculate the
            did you                                     in a wiki
                                     in a wiki
   calculatesummary?
             the
    summary?                     How do I link to
        How do I describe       clinical systems?
        the compound I’mdescribe
                 How do I
         shipping tocompound I’m                  How do I link to
                 the you?
                                                  clinical systems?
                  shipping to you?
Pistoia Current/Emerging Activities - plotted


Vocabulary          Disease
 Services          Knowledge
                 Services (SESL)



               Chemical
               Rendering



                                ELN
             Sequence          Query
              Services          Data
                              Services
Domain Example:
             Initiatives in
             Biology Standards

Pistoia – Curzon Initiative
Pistoia – Curzon Initiative

 • Biomedical Knowledge Integration

 • External Bio-Services Standards

AstraZeneca            GSK                    Pfizer
Ian Dix (AZ)           Mike Barnes (GSK)      Cory Brouwer (Pfizer)
Niklas Blomberg (AZ)   Chris Larminie (GSK)   Bryn Williams-Jones (Pfizer)
Nick Lynch (AZ)        Ashley George (GSK)    Lee Harland (Pfizer)
2 key needs in Biomedical KM

1. Semantic standards in information supply
   chain (commercial & academic)
  – Standardisation of analysis tool interfaces
2. Push model for knowledge access
  – Information awareness, access & mapping is
    key activity for internal information
    professionals
  – Can we move to a model where content
    owners/generators can ‘advertise’ content
    assets?
Building an open services
infrastructure
 SERVICES              Application
                                                    Define needs; Design algorithms;
                      (Knowledge)                   Develop “plug-in” architectures?
                      e.g. Target Dossiers;
                       SAR Visualisation;
                       Fact Visualisation


                   Assertions                     Define needs; Contribute algorithms
                                                   & develop tools (e.g. text mining);
                    e.g. Gene-to-Disease;            Enhance existing approaches
                    Compound-to-Target;
                     Compound-to-ADR

                                                    Support existing standards; Drive
                   Standards                       new DD-relevant ontologies; Work
                                                            with publishers
                     Ontology/taxonomy;
                 Minimum information guide;
               Dictionaries; Interchage mapping


                          Data                           Defining needs; Knowledge;
                                                              Data Contribution
            Targets; Chemistry; Pharmacology;
                    Literature; Patents
Biomedical Knowledge Service
  Framework
                                                                     Multiple
                                                                     Consumers

              Target           Compound    Disease         Network   Knowledge
              Dossier          Dossier     Dossier           Viz     Applications


         Service Layer                                Std Public     Common
                                                                     Proprietary
Open     Assertion & Meta Data Mgmt                  Vocabularies    Service
                                                                     Service
Stds     Transform / Translate                        Business       Broker
                                                                     Broker
Consumer Integrator                                     Rules
Firewall

Supplier                                                               Content
Firewall                                                               Suppliers
                        Db 2
                                                                        Effort required
                                           Db 4                         to fit DBs to
           Corpus 1                                                     service layer
                                    Db 3               Corpus 5
Pistoia Alliance:
             Chemistry Domain

WORKING GROUP UPDATE:
ELN QUERY SERVICES
ELN Query Services Working Group

• Purpose
  – To increase the quality of scientific decision-making through superior
    exploitation of integrated cross-domain knowledge

• Goals
  – To define a standard for an ELN data mart and its query
    services, encompassing information from multiple domain
    sources, whether internal or externally derived, and independent of any
    one technology provider
  – Enable knowledge mining and alerting, including a published API to
    enable data exploitation by external systems
ELN Query Services: Progress

    ACKNOWLEDGEMENTS                    • Kick off meeting April
     ELN Query Services Working Group     2009
                                           – Scope identification
•   Richard Bolton (GSK)                   – Requirements definition
     •   Working Group Chair                 and consolidation
•   Uwe Geissler (Novartis)             • Progress
•   David Drake (AstraZeneca)              – Biweekly meetings held for
•   Steve Trudel (Pfizer)                    Interface Discussions
•   Nick Lynch (AstraZeneca)               – User story collection and
•   Kevin Hebbel (Pfizer)                    consolidation
                                           – Active use of Ning Site for
                                             communication
ELN Query Services: Scope

              • Define and publish high-level foundation
                design principles for an ELN data mart
                and its query services
              • Design and implement a prototype version
                of a synthetic chemistry ELN data mart
                using information from the Discovery
                Chemistry workflow
              • System independent query interface &
                tools accessing via a published API
              • Expand the data model to incorporate
                data from ELN sources across the life
                science space - biology, pharmaceutical
                sciences and analytical sciences
ELN Query Services:
    Logical breakdown of project
                          Today
                                   Expanded ELN
                                   Working Group
                                     Phase 2                    Phase 3                           Phase 4
     Phase 1
                                     Services                  Prototype                        Production
   Requirements
                                      Design                 implementation                   implementation


-User stories                 Data Query Services        - Test and refine ETL process;     - QA cycles and bug fixing
                              design;                    - Test and optimise data mart;     [Alpha; Beta 1; Beta 2; FC]
-Requirements consolidation
                              - ETL process design;      - Test E-Notebook add-in to call
                                                                                            - User Acceptance Testing
                              - ETL validation           the alerting service & fix any
                              mechanism;                 defects;
                              - Alerting service & GUI   - Test Search Appliance API
                              changes;                   using prototype search
                              - Search Appliance API     interface & fix any defects
                              definitions                - Create system documentation


    Defined tollgates between phases
ELN Query Services: Requirements

                • To provide the ability to rapidly and flexibly search
                  ELN experiment information
  Phase 1:
 Requirements   • Readily accessible from within the ELN and also
                  to external systems or services
                • Enable comprehensive reporting based on ELN
                  data
                • Alerting capabilities to provide added-value
                  information and to optimise decision making
                • To be able to segment the data services based
                  on security roles
                • Allow drill-down to experiment details from
                  resultant hit set
                • Built on flexible service-oriented architecture
                    – Web services interfaces for querying and retrieval
ELN Query Services: Phase 1
 Personas - Roles

                                                        Name                      Persona
                                                                 Chemist works in lab 80% of time preparing
                                                        Anna     compounds
Anna enters
a reaction...
                                     Dave has a
                                      list of ....
                                                         Bert    CRO chemist (external)
                                                        Cathy    Lab Manager works in lab 20% of time.
    John is using
                                                        Dave     Alliance/Collaboration manager
      another
     application
       that ....
                                              Bert
                                           wonders if
                                           his group
                                                        Enid     Stores person
                                            has.....
                                                        Fred     Biologist
                                                        Grace    General user
                    Cathy needs
                    a chart for...

                                                        Hector   Analyst (physical chemistry, spectroscopist)

                                                                 Department head, does not do any
                                                        Irene    laboratory work
                                                        John     Records Manager
ELN Query Services: Phase 1
   Story Types
   Story type                           Purpose                                                Goal
Ad hoc chemistry An ELN user submits a query using an ELN                To provide faster searching of the Med Chem ELN
query            search interface. The ELN Data Mart returns the         via its built-in search interface
                     results which are rendered in the results table.
                                                                         To provide rapid searching of the Med Chem ELN
                     A non-ELN user submits a query using a web-         data for non-ELN users
                     search interface. The ELN Data Mart returns the
                     results which are rendered into HTML.

Interface derived An external system or service submits a query to To provide access to ELN data from an external
query (Search     the ELN data mart API. The query is executed and system or service.
                  the required data extracted. The results are
API)
                     returned to the external system or service

Metrics/Reporting A manager executes a stored query (providing           To provide on demand reports for monitoring targets,
                     variable parameters where necessary). The ELN       measuring value and planning future strategy
                     Data Mart returns the results which are then
                     rendered using a pre-defined template to generate
                     a formatted report. Could include both on demand
                     and batch based reporting.
Live Alerting        A user action triggers a stored query within the E- To provide added-value information during the day-
                     Notebook based on the data entered. The ELN         to-day use of the Med Chem ELN to optimise
                     Data Mart returns related data which is displayed decision making
                     to the chemist.
ELN Query Services: Phase 1
   User Story Collection

• Working group  Consolidation of Stories
Type of Story              Indication of story such as ad hoc query, interface
                          drive, metrics/reporting, live alerting, security
User Story detail         The business based description of the process the
                          user wishes to initiate.
User story input detail The inputs generated for successful outcome
User story output detail The results of the data mart action returned to the
                          user
Requirements detail       Extraction of specific data mart requirements based
                          on the stated use input and system output
Other implications        Things that need to be considered further or need
                          investigating to enable clear requirements to be
                          stated.
Data entities input list The primary data entities the user story will call on in
                          standardized form.
Data entities output list The primary data entities the user story will call on in
                          standardized form.
User feedback on story
(includes non             What next once the user receives results, and how
functional stories)       is that data consumed and used
ELN Query Services: Phase 1
      User Story Collection
  • Roles, story                                        ELN X
    types, questions, inp
    uts...
Anna enters
                                                                  • Formats
a reaction...

                                                        ELN Y                • Implications
                                    Dave has a
                                     list of ....




      Charlie is
    using another
                                                       Internal
     application
       that ....
                                             Bob
                                          wonders if    Info 1          Hmm...Now I
                                                                         need to .....
                                          his group                     What about...
                                           has.....



                                                       External
                                                        Info A
                    Suzy needs a
                     chart for...



                                                       External    • Output data entities
                                                        Info B
                • Input data entities
                                                         ....          • Results Detail
 • Requirements Detail
ELN Query Services: Phase 1
User Story Example: US_AHQ_001
User Story detail      Anna wishes to find reactions and data for a particular conversion
User story input       Anna enters a reaction/transformation of interest and selects either
detail                 required retrieval fields or expects to retrieve all the experiment
User story output      User receives a list containing all experiments that fit the conversion
detail                 along with a selected set of fields from the mart in an appropriately
                       sorted sequence (user defined sort) with the selected data available

Data entities input    reaction:structure
list                   transformation:structure
                       (list of fields to be retrieved)
Data entities output   reaction:structure
list                   transformation:structure
                       reaction_id:integer
                       yield: float
                       scientist:text
                       site/location:text
                       experiment_detail:text
                       (other fields requested)
ELN Query Services: Phase 1
User Story Example: US_IDQ_003
User Story detail     Enid is using stock control system needs to identify all reagents that
                      have not been used in the past five years in her annual audit.
User story input      Enid enters a list of ids of reagents. The system will need to expand
detail                this id into structure and all possible synonyms than use these to search
                      exhaustively for these as used in any reaction over the indicated time
                      period. Both structure and experiment fields will likely need to be
                      searched
User story output     list of id's as input with summary usage stats showing how often used
detail                and when. Enid id unlikely to wish to drill down to understand usage,
                      she is only interested in finding those reagents that have not been used.
                      If a reagent has a single use close to her time interval she may want to
                      drill down to the scientist to ask them for their opinion on keeping the
                      reagent.
Data entities input   reagent_id:string
list                  date:reange
Data entities         reagent_id:string
output list           reagent_name:string
                      date:date
                      aggregated usage
ELN Query Services
Next Steps
             • Next Steps
               – Pistoia Publicaton process
               – Checkpoint and onto Phase 2
               – Active use of Ning Site for
                 communication and collaboration
ELN Query Services

            • Search, Performance, Reporting...
            • Are you actively and effectively
              using your ELN data?
            • How are you accessing your data?
            • Querying across data sources:
               –   Internal vs. external data
               –   Data driven decision making
               –   Balance of data usage
               –   Accessibility
               –   Combined searches, independent
               –   ...
For More Information

• Pistoiaalliance.org
  – Vision, Overview, How to Join




• Ning Site
  – Pistoia Alliance Members only
An Intentional Segue into
Technology Transfer
• Grant or License Access to Pfizer-developed
  assets to support pre-competitive components of
  research, development, and medical operations.
• Philanthropic and capitalistic (revenue
  generation) opportunities.
• Examples:
  –   Biological Protocol Definitions/Models
  –   Electronic Notebooks (IP Traceability) for Chemistry
  –   Computational Surrogates for ADME/T Assays
  –   Research Outsourcing/Bidding/Tracking Tools
Discussion
Additional Information on Pistoia
Pistoia Roadmap - Overview
               2008                                                     2009

                                                               Network/Pharma
 Early Build               Biology Awareness                      Awareness
                                                                     Portfolio build
               Externalisation                             Extended Strategy Build


                  Governance
                                 Governance                                                           Nor
                                  Board and                   Enrolment - priority
                    Model
                                   Officers
                                                                                                      mal

                            Legal Setup
                                          Finance setup & budget planning
                                             Operating
                                             processes
                                       Communications
                                                                             Biology/Disease Area
                  Lhasa                                                           Programme


                                                             ELN Data Mart
                                              Chemical Renderer
          Decision to
       create Pistoia as                        Official
        Not for profit                          Launch                                              Review
Open Collaboration—Process

Problem    Demand          Request                    Develop       Solution
                                                                    Delivery
           Collaborating
            Companies
               input                                    Decide
                                                        how to
                                                       develop
                                                       together
  Share
             Elaborate                      Decide
 outside                    Decide to                 Prepare 3rd   3rd party
             Common                         how to
company                    collaborate                   party       hosting
               Needs                        develop
  walls
                                                        Prepare
                                         Open         tender/RFP
                                    Collaborations
               Open                     opens         Traditional
           Collaboration            opportunities      Company
             Interface                  earlier        Interface
                                                                                52
Pistoia Alignment                                                  •Do we need an
                                                                    advisory board? CDISC


                                                         Advisory
 Industry                                 Members         Board?
Standards
  Groups            Board of
                    Directors                                                               Domain
                                          Technical              Domain                     Steering
        Industry                          Committee           Classification                 Groups
       Challenges


                           Enabling
        Disease
                                            Knowledge and Information Services
                           Vocabulary

     Pharmacology
                          Visualisation
                                             Application Integration Standards
            DMPK           Workflow

                                             Biology    Chemistry       TranslationalWorking
        Safety                  Others         Data        Data             Data     Groups
                                             Services    Services            Services

Mais conteúdo relacionado

Semelhante a Pistoia Alliance Oct 2009 (Presented At Cdd)

The ADD Effect In Clinical Development
The ADD Effect In Clinical DevelopmentThe ADD Effect In Clinical Development
The ADD Effect In Clinical DevelopmentSanjay Modi
 
boston scientific2005_annual
boston scientific2005_annualboston scientific2005_annual
boston scientific2005_annualfinance28
 
Lazard Capital Markets Research Report on Ventrus Biosciences (NASDAQ: VTUS; ...
Lazard Capital Markets Research Report on Ventrus Biosciences (NASDAQ: VTUS; ...Lazard Capital Markets Research Report on Ventrus Biosciences (NASDAQ: VTUS; ...
Lazard Capital Markets Research Report on Ventrus Biosciences (NASDAQ: VTUS; ...ProActive Capital Resources Group
 
Parallel Session 3.1.3 Emerging Technologies - Horizon Scanning
Parallel Session 3.1.3 Emerging Technologies - Horizon Scanning Parallel Session 3.1.3 Emerging Technologies - Horizon Scanning
Parallel Session 3.1.3 Emerging Technologies - Horizon Scanning NHSScotlandEvent
 
Ezose Final Presentation
Ezose Final PresentationEzose Final Presentation
Ezose Final Presentationejmillennium
 
boston scientific 2005_annual
boston scientific 2005_annualboston scientific 2005_annual
boston scientific 2005_annualfinance28
 
boston scientific2005_annual
boston scientific2005_annualboston scientific2005_annual
boston scientific2005_annualfinance28
 
boston scientific2005_annual
boston scientific2005_annualboston scientific2005_annual
boston scientific2005_annualfinance28
 
Clinical rd presentation 10 jan2012_sharma
Clinical rd presentation 10 jan2012_sharmaClinical rd presentation 10 jan2012_sharma
Clinical rd presentation 10 jan2012_sharmaTTC, llc
 
Internship project presentation
Internship project presentationInternship project presentation
Internship project presentationAlok Jain
 
BioEntrepreneurship: Exploiting Early Staged Discoveries
BioEntrepreneurship: Exploiting Early Staged DiscoveriesBioEntrepreneurship: Exploiting Early Staged Discoveries
BioEntrepreneurship: Exploiting Early Staged DiscoveriesMaRS Discovery District
 
Diffusion of innovation beyond the tipping point m goulbourne 2007
Diffusion of innovation beyond the tipping point   m goulbourne 2007Diffusion of innovation beyond the tipping point   m goulbourne 2007
Diffusion of innovation beyond the tipping point m goulbourne 2007Michelle Goulbourne @ DiaMind Health
 
Elias Zerhouni - January 22, BioForward Breakfast Event Presentation
Elias Zerhouni - January 22, BioForward Breakfast Event PresentationElias Zerhouni - January 22, BioForward Breakfast Event Presentation
Elias Zerhouni - January 22, BioForward Breakfast Event PresentationBioForward
 
Sweet sensors lecture 8 resources
Sweet sensors lecture 8 resourcesSweet sensors lecture 8 resources
Sweet sensors lecture 8 resourcesStanford University
 
Aestus Non Confidential Intro 062410
Aestus Non Confidential Intro 062410Aestus Non Confidential Intro 062410
Aestus Non Confidential Intro 062410djlavery
 
Dalradian corporate presentation march 15 2012 final
Dalradian corporate presentation march 15 2012 finalDalradian corporate presentation march 15 2012 final
Dalradian corporate presentation march 15 2012 finalDalradianResource
 
Translating Clinical Guidelines into Knowledge-guided Decision Support
Translating Clinical Guidelines into Knowledge-guided Decision SupportTranslating Clinical Guidelines into Knowledge-guided Decision Support
Translating Clinical Guidelines into Knowledge-guided Decision SupportPlan de Calidad para el SNS
 

Semelhante a Pistoia Alliance Oct 2009 (Presented At Cdd) (20)

The ADD Effect In Clinical Development
The ADD Effect In Clinical DevelopmentThe ADD Effect In Clinical Development
The ADD Effect In Clinical Development
 
boston scientific2005_annual
boston scientific2005_annualboston scientific2005_annual
boston scientific2005_annual
 
Lazard Capital Markets Research Report on Ventrus Biosciences (NASDAQ: VTUS; ...
Lazard Capital Markets Research Report on Ventrus Biosciences (NASDAQ: VTUS; ...Lazard Capital Markets Research Report on Ventrus Biosciences (NASDAQ: VTUS; ...
Lazard Capital Markets Research Report on Ventrus Biosciences (NASDAQ: VTUS; ...
 
Lazard research report ventrus
Lazard research report ventrusLazard research report ventrus
Lazard research report ventrus
 
Ion express lecture 7 partners
Ion express lecture 7 partnersIon express lecture 7 partners
Ion express lecture 7 partners
 
Parallel Session 3.1.3 Emerging Technologies - Horizon Scanning
Parallel Session 3.1.3 Emerging Technologies - Horizon Scanning Parallel Session 3.1.3 Emerging Technologies - Horizon Scanning
Parallel Session 3.1.3 Emerging Technologies - Horizon Scanning
 
Ezose Final Presentation
Ezose Final PresentationEzose Final Presentation
Ezose Final Presentation
 
boston scientific 2005_annual
boston scientific 2005_annualboston scientific 2005_annual
boston scientific 2005_annual
 
boston scientific2005_annual
boston scientific2005_annualboston scientific2005_annual
boston scientific2005_annual
 
boston scientific2005_annual
boston scientific2005_annualboston scientific2005_annual
boston scientific2005_annual
 
Clinical rd presentation 10 jan2012_sharma
Clinical rd presentation 10 jan2012_sharmaClinical rd presentation 10 jan2012_sharma
Clinical rd presentation 10 jan2012_sharma
 
Internship project presentation
Internship project presentationInternship project presentation
Internship project presentation
 
BioEntrepreneurship: Exploiting Early Staged Discoveries
BioEntrepreneurship: Exploiting Early Staged DiscoveriesBioEntrepreneurship: Exploiting Early Staged Discoveries
BioEntrepreneurship: Exploiting Early Staged Discoveries
 
Diffusion of innovation beyond the tipping point m goulbourne 2007
Diffusion of innovation beyond the tipping point   m goulbourne 2007Diffusion of innovation beyond the tipping point   m goulbourne 2007
Diffusion of innovation beyond the tipping point m goulbourne 2007
 
Elias Zerhouni - January 22, BioForward Breakfast Event Presentation
Elias Zerhouni - January 22, BioForward Breakfast Event PresentationElias Zerhouni - January 22, BioForward Breakfast Event Presentation
Elias Zerhouni - January 22, BioForward Breakfast Event Presentation
 
Sweet sensors lecture 8 resources
Sweet sensors lecture 8 resourcesSweet sensors lecture 8 resources
Sweet sensors lecture 8 resources
 
Aestus Non Confidential Intro 062410
Aestus Non Confidential Intro 062410Aestus Non Confidential Intro 062410
Aestus Non Confidential Intro 062410
 
Cipher Pharmaceuticals
Cipher PharmaceuticalsCipher Pharmaceuticals
Cipher Pharmaceuticals
 
Dalradian corporate presentation march 15 2012 final
Dalradian corporate presentation march 15 2012 finalDalradian corporate presentation march 15 2012 final
Dalradian corporate presentation march 15 2012 final
 
Translating Clinical Guidelines into Knowledge-guided Decision Support
Translating Clinical Guidelines into Knowledge-guided Decision SupportTranslating Clinical Guidelines into Knowledge-guided Decision Support
Translating Clinical Guidelines into Knowledge-guided Decision Support
 

Mais de Chris Waller

Translational Data Science_clean
Translational Data Science_cleanTranslational Data Science_clean
Translational Data Science_cleanChris Waller
 
Innovation at the Edge_Final
Innovation at the Edge_FinalInnovation at the Edge_Final
Innovation at the Edge_FinalChris Waller
 
Building a Culture
Building a CultureBuilding a Culture
Building a CultureChris Waller
 
Building a Culture of Model-driven Drug Discovery at Merck
Building a Culture of Model-driven Drug Discovery at MerckBuilding a Culture of Model-driven Drug Discovery at Merck
Building a Culture of Model-driven Drug Discovery at MerckChris Waller
 
How to Create a Big Data Culture in Pharma
How to Create a Big Data Culture in PharmaHow to Create a Big Data Culture in Pharma
How to Create a Big Data Culture in PharmaChris Waller
 
Breaking Down Information Silos
Breaking Down Information SilosBreaking Down Information Silos
Breaking Down Information SilosChris Waller
 
BioIT World 2011 eHealth
BioIT World 2011 eHealthBioIT World 2011 eHealth
BioIT World 2011 eHealthChris Waller
 
Precompetitive Collaborations
Precompetitive CollaborationsPrecompetitive Collaborations
Precompetitive CollaborationsChris Waller
 
Science As A Business
Science As A BusinessScience As A Business
Science As A BusinessChris Waller
 
MDL UGM April 2007
MDL UGM April 2007MDL UGM April 2007
MDL UGM April 2007Chris Waller
 

Mais de Chris Waller (10)

Translational Data Science_clean
Translational Data Science_cleanTranslational Data Science_clean
Translational Data Science_clean
 
Innovation at the Edge_Final
Innovation at the Edge_FinalInnovation at the Edge_Final
Innovation at the Edge_Final
 
Building a Culture
Building a CultureBuilding a Culture
Building a Culture
 
Building a Culture of Model-driven Drug Discovery at Merck
Building a Culture of Model-driven Drug Discovery at MerckBuilding a Culture of Model-driven Drug Discovery at Merck
Building a Culture of Model-driven Drug Discovery at Merck
 
How to Create a Big Data Culture in Pharma
How to Create a Big Data Culture in PharmaHow to Create a Big Data Culture in Pharma
How to Create a Big Data Culture in Pharma
 
Breaking Down Information Silos
Breaking Down Information SilosBreaking Down Information Silos
Breaking Down Information Silos
 
BioIT World 2011 eHealth
BioIT World 2011 eHealthBioIT World 2011 eHealth
BioIT World 2011 eHealth
 
Precompetitive Collaborations
Precompetitive CollaborationsPrecompetitive Collaborations
Precompetitive Collaborations
 
Science As A Business
Science As A BusinessScience As A Business
Science As A Business
 
MDL UGM April 2007
MDL UGM April 2007MDL UGM April 2007
MDL UGM April 2007
 

Pistoia Alliance Oct 2009 (Presented At Cdd)

  • 1. The Pistoia Alliance pistoiaalliance.org A Construct for Pre-competitive Collaborations Chris L. Waller, Ph.D. Pfizer Collaborative Drug Discovery Annual Meeting San Francisco, CA October 2009
  • 2. Agenda • Introduction • Origins of Pistoia – History – Industry Drivers – Technology Trends • Scope and Operations of Pistoia – Mission, Membership, Governance – Projects and Deliverables • Discussion
  • 3. R&D: Long, Expensive, and Risky Target Chemical Clinical Launch Selection Selection Trials Discovery (2-10 years) Pre-clinical Testing Laboratory and animal testing Phase 1 20-80 healthy volunteers - safety and dosage Phase 2 100-300 patient volunteers efficacy & safety Phase 3 3,000-5,000 patient volunteers used to monitor adverse reactions to long-term use FDA Review/ Approval Years 0 2 4 6 8 10 12 14 16 Cost = $1.3B/new drug
  • 4. Productivity is Decreasing Industry R&D Annual NME Expense Approvals ($ Billions) $35 200 R&D Investment 180 $30 NME Approvals 160 $25 140 $20 120 100 $15 80 $10 60 40 $5 20 $0 0 1980 1984 1988 1992 1996 2000 2004 Source: PhRMA, FDA, Lehman Brothers; The 2004 Industry R&D Expense is an estimate
  • 5. Chris’s Mission Statement • Foster collaborations between pharmaceutical, biotechnology, technology, academic, and government organizations in pre- competitive space to develop and promote the use of standards, identify partnerships, and transfer technology in order to drive greater process efficiency and lower costs.
  • 6. Pre-competitive • Refers to standards, data, or processes that are common across an industry and where the adoption, use, or prosecution of which provides no competitive advantage relative to peers.
  • 7. Leading Healthcare Data Exchange Standards Clinical Materials Management Billing, System claims HL7 X12N reimbursement Retail Pharmacy X12N / HL7 (Non-US only) Orders & Reimbursement NCPDP HL7 Immunization Healthcare Database Waveforms HL7 Information System HL7, X12N Images, DICOM Agency Reporting pictures HL7 HL7, X12N IEEE MIB, ASTM Bedside Adverse Provider Instruments Events Reporting Repository Image from Abdul-Malik Shakir
  • 8. Background—How it all started • In Pistoia, Italy • Meeting of GSK, AZ, Pfizer and Novartis—identified similar challenges and frustrations in the IT/Informatics sector of Pharmaceutical Discovery 8
  • 9. Industry Driver: Externalization Cost pressures, disruptive technologies, and other forces often drive business processes to be externalized. Fully Internal PHARMA DESIGN SYNTHESIZE REGISTER DISTRIBUTE ASSAY REPORT Model Selectively PHARMA DESIGN DISTRIBUTE PHARMA Integrated CHEM CRO Model SYNTHESIZE CHEM BIO CRO ASSAY BIO DATA CRO REGISTER REPORT DATA
  • 10. Emerging Net-centric Pharma Processes PHARMA CRO 1 1 PHARMA CRO 2 2 PHARMA CRO 3 3 CRO 4
  • 11. Inconsistent Semantics degrade Effective Communication C B A The result from our proprietary assay is “B” CRO But we only record numbers in our assays!! PHARMA
  • 12. Greater Challenge: Unknown Semantic Collisions Revealing assumptions is an essential component of effective communication. Image/quote from Abdul-Malik Shakir
  • 13. Opportunity: Changing Tech Landscape More Robust Technologies • Web 2.0 • Services-Oriented Architecture • Software-as-a-Service • Open Source Initiatives More Robust External Content • Publicly available chem and bio sources • Richer literature content • Academic Sources of Tools and Data
  • 14. The Path Forward: Standardize, Simplify, Centralize • Standardize our interfaces and messages • Simplify our cross-industry architectures and support models • Centralize services to reap economies of scale and scope
  • 15. Mission of Pistoia • Pistoia is the BRIDGE to cross the chasm to a more agile pre-competitive environment STANDARDIZE SIMPLIFY CENTRALIZE PISTOIA MEMBERS SUPPLIERS
  • 16. Learn from Other Industries Transportation Geospatial Banking Retail Clinical Automotive Healthcare
  • 17. Pistoia Description and Purpose Mission To streamline pre-competitive workflow elements of pharmaceutical research and development by specifying common business terms, relationships and processes Goal • Develop taxonomies and vocabularies, application interface specifications, data dictionaries, data models, etc. • Establish standards that will be embraced by producers and consumers of pre-competitive workflows 17
  • 18. Pistoia Membership as of: August 26, 2009 >65 Individuals from 18 member organizations
  • 19. Pistoia Alliance Organisation Develops roadmap Board of Final approval of technical standards Directors Voting Members (pharma, biotech) Non-Voting Members (vendors, academics) Officers President, Secretary, Treasurer, PM, Communica tions Develop standards Technical Submit standards to Gov & Strat Board Committee Finalize standard and publish Observe use of standard and evolve if necessary 19
  • 20. Pistoia Standards Process Governance & Working Groups Pistoia Operations Community Governance Software and & Strategy submit Service Board Providers propose, Technical & comment Standards Pharma/ Operational Teams BioTech/Agro Team publish Not for coordinate Profit (e.g. IMI, EBI) 20
  • 22. Pistoia Domains Focused on business workflows/supply chains Enabling Knowledge and Information Vocabulary Services Visualisation Workflow Application Integration Others Biology Chemistry Translational Data Data Data Services Services Services
  • 23. Capturing Demand using Domain Framework Need a disease How to enrich ontology Need a How to enrich literature with disease literature with semantic tags ontology semantic tags What is this raw How to show How to show What is this How did you data? raw chemical structures chemical structures data? Howcalculate the did you in a wiki in a wiki calculatesummary? the summary? How do I link to How do I describe clinical systems? the compound I’mdescribe How do I shipping tocompound I’m How do I link to the you? clinical systems? shipping to you?
  • 24. Pistoia Current/Emerging Activities - plotted Vocabulary Disease Services Knowledge Services (SESL) Chemical Rendering ELN Sequence Query Services Data Services
  • 25. Domain Example: Initiatives in Biology Standards Pistoia – Curzon Initiative
  • 26. Pistoia – Curzon Initiative • Biomedical Knowledge Integration • External Bio-Services Standards AstraZeneca GSK Pfizer Ian Dix (AZ) Mike Barnes (GSK) Cory Brouwer (Pfizer) Niklas Blomberg (AZ) Chris Larminie (GSK) Bryn Williams-Jones (Pfizer) Nick Lynch (AZ) Ashley George (GSK) Lee Harland (Pfizer)
  • 27. 2 key needs in Biomedical KM 1. Semantic standards in information supply chain (commercial & academic) – Standardisation of analysis tool interfaces 2. Push model for knowledge access – Information awareness, access & mapping is key activity for internal information professionals – Can we move to a model where content owners/generators can ‘advertise’ content assets?
  • 28. Building an open services infrastructure SERVICES Application Define needs; Design algorithms; (Knowledge) Develop “plug-in” architectures? e.g. Target Dossiers; SAR Visualisation; Fact Visualisation Assertions Define needs; Contribute algorithms & develop tools (e.g. text mining); e.g. Gene-to-Disease; Enhance existing approaches Compound-to-Target; Compound-to-ADR Support existing standards; Drive Standards new DD-relevant ontologies; Work with publishers Ontology/taxonomy; Minimum information guide; Dictionaries; Interchage mapping Data Defining needs; Knowledge; Data Contribution Targets; Chemistry; Pharmacology; Literature; Patents
  • 29. Biomedical Knowledge Service Framework Multiple Consumers Target Compound Disease Network Knowledge Dossier Dossier Dossier Viz Applications Service Layer Std Public Common Proprietary Open Assertion & Meta Data Mgmt Vocabularies Service Service Stds Transform / Translate Business Broker Broker Consumer Integrator Rules Firewall Supplier Content Firewall Suppliers Db 2 Effort required Db 4 to fit DBs to Corpus 1 service layer Db 3 Corpus 5
  • 30. Pistoia Alliance: Chemistry Domain WORKING GROUP UPDATE: ELN QUERY SERVICES
  • 31. ELN Query Services Working Group • Purpose – To increase the quality of scientific decision-making through superior exploitation of integrated cross-domain knowledge • Goals – To define a standard for an ELN data mart and its query services, encompassing information from multiple domain sources, whether internal or externally derived, and independent of any one technology provider – Enable knowledge mining and alerting, including a published API to enable data exploitation by external systems
  • 32. ELN Query Services: Progress ACKNOWLEDGEMENTS • Kick off meeting April ELN Query Services Working Group 2009 – Scope identification • Richard Bolton (GSK) – Requirements definition • Working Group Chair and consolidation • Uwe Geissler (Novartis) • Progress • David Drake (AstraZeneca) – Biweekly meetings held for • Steve Trudel (Pfizer) Interface Discussions • Nick Lynch (AstraZeneca) – User story collection and • Kevin Hebbel (Pfizer) consolidation – Active use of Ning Site for communication
  • 33. ELN Query Services: Scope • Define and publish high-level foundation design principles for an ELN data mart and its query services • Design and implement a prototype version of a synthetic chemistry ELN data mart using information from the Discovery Chemistry workflow • System independent query interface & tools accessing via a published API • Expand the data model to incorporate data from ELN sources across the life science space - biology, pharmaceutical sciences and analytical sciences
  • 34. ELN Query Services: Logical breakdown of project Today Expanded ELN Working Group Phase 2 Phase 3 Phase 4 Phase 1 Services Prototype Production Requirements Design implementation implementation -User stories Data Query Services - Test and refine ETL process; - QA cycles and bug fixing design; - Test and optimise data mart; [Alpha; Beta 1; Beta 2; FC] -Requirements consolidation - ETL process design; - Test E-Notebook add-in to call - User Acceptance Testing - ETL validation the alerting service & fix any mechanism; defects; - Alerting service & GUI - Test Search Appliance API changes; using prototype search - Search Appliance API interface & fix any defects definitions - Create system documentation Defined tollgates between phases
  • 35. ELN Query Services: Requirements • To provide the ability to rapidly and flexibly search ELN experiment information Phase 1: Requirements • Readily accessible from within the ELN and also to external systems or services • Enable comprehensive reporting based on ELN data • Alerting capabilities to provide added-value information and to optimise decision making • To be able to segment the data services based on security roles • Allow drill-down to experiment details from resultant hit set • Built on flexible service-oriented architecture – Web services interfaces for querying and retrieval
  • 36. ELN Query Services: Phase 1 Personas - Roles Name Persona Chemist works in lab 80% of time preparing Anna compounds Anna enters a reaction... Dave has a list of .... Bert CRO chemist (external) Cathy Lab Manager works in lab 20% of time. John is using Dave Alliance/Collaboration manager another application that .... Bert wonders if his group Enid Stores person has..... Fred Biologist Grace General user Cathy needs a chart for... Hector Analyst (physical chemistry, spectroscopist) Department head, does not do any Irene laboratory work John Records Manager
  • 37. ELN Query Services: Phase 1 Story Types Story type Purpose Goal Ad hoc chemistry An ELN user submits a query using an ELN To provide faster searching of the Med Chem ELN query search interface. The ELN Data Mart returns the via its built-in search interface results which are rendered in the results table. To provide rapid searching of the Med Chem ELN A non-ELN user submits a query using a web- data for non-ELN users search interface. The ELN Data Mart returns the results which are rendered into HTML. Interface derived An external system or service submits a query to To provide access to ELN data from an external query (Search the ELN data mart API. The query is executed and system or service. the required data extracted. The results are API) returned to the external system or service Metrics/Reporting A manager executes a stored query (providing To provide on demand reports for monitoring targets, variable parameters where necessary). The ELN measuring value and planning future strategy Data Mart returns the results which are then rendered using a pre-defined template to generate a formatted report. Could include both on demand and batch based reporting. Live Alerting A user action triggers a stored query within the E- To provide added-value information during the day- Notebook based on the data entered. The ELN to-day use of the Med Chem ELN to optimise Data Mart returns related data which is displayed decision making to the chemist.
  • 38. ELN Query Services: Phase 1 User Story Collection • Working group  Consolidation of Stories Type of Story Indication of story such as ad hoc query, interface drive, metrics/reporting, live alerting, security User Story detail The business based description of the process the user wishes to initiate. User story input detail The inputs generated for successful outcome User story output detail The results of the data mart action returned to the user Requirements detail Extraction of specific data mart requirements based on the stated use input and system output Other implications Things that need to be considered further or need investigating to enable clear requirements to be stated. Data entities input list The primary data entities the user story will call on in standardized form. Data entities output list The primary data entities the user story will call on in standardized form. User feedback on story (includes non What next once the user receives results, and how functional stories) is that data consumed and used
  • 39. ELN Query Services: Phase 1 User Story Collection • Roles, story ELN X types, questions, inp uts... Anna enters • Formats a reaction... ELN Y • Implications Dave has a list of .... Charlie is using another Internal application that .... Bob wonders if Info 1 Hmm...Now I need to ..... his group What about... has..... External Info A Suzy needs a chart for... External • Output data entities Info B • Input data entities .... • Results Detail • Requirements Detail
  • 40. ELN Query Services: Phase 1 User Story Example: US_AHQ_001 User Story detail Anna wishes to find reactions and data for a particular conversion User story input Anna enters a reaction/transformation of interest and selects either detail required retrieval fields or expects to retrieve all the experiment User story output User receives a list containing all experiments that fit the conversion detail along with a selected set of fields from the mart in an appropriately sorted sequence (user defined sort) with the selected data available Data entities input reaction:structure list transformation:structure (list of fields to be retrieved) Data entities output reaction:structure list transformation:structure reaction_id:integer yield: float scientist:text site/location:text experiment_detail:text (other fields requested)
  • 41. ELN Query Services: Phase 1 User Story Example: US_IDQ_003 User Story detail Enid is using stock control system needs to identify all reagents that have not been used in the past five years in her annual audit. User story input Enid enters a list of ids of reagents. The system will need to expand detail this id into structure and all possible synonyms than use these to search exhaustively for these as used in any reaction over the indicated time period. Both structure and experiment fields will likely need to be searched User story output list of id's as input with summary usage stats showing how often used detail and when. Enid id unlikely to wish to drill down to understand usage, she is only interested in finding those reagents that have not been used. If a reagent has a single use close to her time interval she may want to drill down to the scientist to ask them for their opinion on keeping the reagent. Data entities input reagent_id:string list date:reange Data entities reagent_id:string output list reagent_name:string date:date aggregated usage
  • 42. ELN Query Services Next Steps • Next Steps – Pistoia Publicaton process – Checkpoint and onto Phase 2 – Active use of Ning Site for communication and collaboration
  • 43. ELN Query Services • Search, Performance, Reporting... • Are you actively and effectively using your ELN data? • How are you accessing your data? • Querying across data sources: – Internal vs. external data – Data driven decision making – Balance of data usage – Accessibility – Combined searches, independent – ...
  • 44. For More Information • Pistoiaalliance.org – Vision, Overview, How to Join • Ning Site – Pistoia Alliance Members only
  • 45. An Intentional Segue into Technology Transfer • Grant or License Access to Pfizer-developed assets to support pre-competitive components of research, development, and medical operations. • Philanthropic and capitalistic (revenue generation) opportunities. • Examples: – Biological Protocol Definitions/Models – Electronic Notebooks (IP Traceability) for Chemistry – Computational Surrogates for ADME/T Assays – Research Outsourcing/Bidding/Tracking Tools
  • 48. Pistoia Roadmap - Overview 2008 2009 Network/Pharma Early Build Biology Awareness Awareness Portfolio build Externalisation Extended Strategy Build Governance Governance Nor Board and Enrolment - priority Model Officers mal Legal Setup Finance setup & budget planning Operating processes Communications Biology/Disease Area Lhasa Programme ELN Data Mart Chemical Renderer Decision to create Pistoia as Official Not for profit Launch Review
  • 49. Open Collaboration—Process Problem Demand Request Develop Solution Delivery Collaborating Companies input Decide how to develop together Share Elaborate Decide outside Decide to Prepare 3rd 3rd party Common how to company collaborate party hosting Needs develop walls Prepare Open tender/RFP Collaborations Open opens Traditional Collaboration opportunities Company Interface earlier Interface 52
  • 50. Pistoia Alignment •Do we need an advisory board? CDISC Advisory Industry Members Board? Standards Groups Board of Directors Domain Technical Domain Steering Industry Committee Classification Groups Challenges Enabling Disease Knowledge and Information Services Vocabulary Pharmacology Visualisation Application Integration Standards DMPK Workflow Biology Chemistry TranslationalWorking Safety Others Data Data Data Groups Services Services Services